

GAMMACAN INTERNATIONAL INC  
Form 8-K  
December 12, 2006

**UNITED STATES SECURITIES AND  
EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 30, 2006**

**GAMMACAN INTERNATIONAL, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**0-32835**  
(Commission File Number)

**33-0956433**  
(IRS Employer Identification No.)

**39 Jerusalem St., Kiryat Ono 55423 Israel**  
(Address of principal executive offices and Zip Code)  
Registrant's telephone number, including area code: **972 3 738 2616**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

-2-

**ITEM 7.01 Regulation FD Disclosure**

On November 30, 2006, GammaCan International, Inc. made a presentation concerning its results regarding the efficacy and safety of IVIG intravenous immunoglobulin in patients with metastatic melanoma at the 5<sup>th</sup> International Congress of Autoimmunity in Sorrento, Italy. The materials utilized during the presentation are filed as Exhibit 99.1 to, and incorporated by reference in, this report. In accordance with Regulation FD, this current report is being filed to publicly disclose all information that was provided in its press release. This report under Item 7.01 is not deemed an admission as to the materiality of any information in this report that is required to be disclosed solely by Regulation FD.

**ITEM 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Presentation Materials.

-3-

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GAMMACAN INTERNATIONAL, INC.**

/s/ Patrick Schnegelsberg  
Patrick Schnegelsberg,  
Chief Executive Officer

Date: December 12, 2006